🔎 Trials Near Me

Dachaigh › Lymphoma Burkitt › Idaho

Sgrùdaidhean clionaigeach Lymphoma Burkitt ann an Idaho

Tha 6 sgrùdaidhean airson Lymphoma Burkitt a’ lorg phàirtichean aig làraichean ann an Idaho.

Bailtean ann an Idaho

Teacsa sgrùdaidh oifigeil (Beurla)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Saint Luke's Cancer Institute - Boise, Boise
A’ fastadhÌre 2
366 Days – 46 Years · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Saint Alphonsus Cancer Care Center-Boise, Boise
  • Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
  • Kootenai Health - Coeur d'Alene, Coeur d'Alene
  • agus 3 a bharrachd
A’ fastadhÌre 3
Aoisean 18 gu 39 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Saint Alphonsus Cancer Care Center-Nampa, Nampa
A’ fastadhÌre 2
Aoisean 18 agus nas sine · Gach gnè · Air ùrachadh 29 Sult 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Saint Luke's Cancer Institute - Boise, Boise
A’ fastadhÌre 2
365 Days · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Saint Luke's Cancer Institute - Boise, Boise
A’ fastadhÌre 2
Aoisean 1 gu 30 · Gach gnè · Air ùrachadh 1 Sult 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Saint Luke's Cancer Institute - Boise, Boise
A’ fastadhÌre 3
365 Days – 25 Years · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT03959085

Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.